Multimodal prediction of dementia with up to 10 years follow up: The Gothenburg MCI study

Journal of Alzheimer's Disease

Volumn 44, Issue 1, 2015, Pages 205-214

  Eckerström, Carl ^a   Olsson, Erik ^a   Klasson, Niklas ^a   Berge, Josef ^a   Nordlund, Arto ^a   Bjerke, Maria ^a   Wallin, Anders ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cerebrospinal fluid; Dementia; Magnetic resonance imaging; Mild cognitive impairment; Neuropsychological test

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PHOSPHORYLATED TAU181 PROTEIN; TAU PROTEIN; TOTAL TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BOSTON NAMING TEST; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REY AUDITORY VERBAL LEARNING TEST; SENSITIVITY AND SPECIFICITY; TRAIL MAKING TEST B; WHITE MATTER LESION; CEREBROSPINAL FLUID; LONGITUDINAL STUDY; MENTAL HEALTH; MIDDLE AGED; PATHOLOGY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AREA UNDER CURVE; DEMENTIA; DISEASE PROGRESSION; FEMALE; HIPPOCAMPUS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; TAU PROTEINS;

EID: 84920847857     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141053     Document Type: Article

References (44)

1. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6, 67-77.
2. Debette S, Markus HS (2010) The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: Systematic review and meta-analysis. BMJ 341, c3666.
3. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM (2004) Cerebral white matter lesions and the risk of dementia. Arch Neurol 61, 1531-1534.
4. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302, 385-393.
5. Nordlund A, Rolstad S, Gothlin M, Edman A, Hansen S, Wallin A (2010) Cognitive profiles of incipient dementia in the Goteborg MCI study. Dementia Geriatr Cogn Disord 30, 403-410.
6. Espinosa A, Alegret M, Valero S, Vinyes-Junque G, Hernandez I, Mauleon A, Rosende-Roca M, Ruiz A, Lopez O, Tarraga L, Boada M (2013) A longitudinal follow-up of 550 mild cognitive impairment patients: Evidence for large conversion to dementia rates and detection of major risk factors involved. J Alzheimers Dis 34, 769-780.
7. Eckerstrom C, Olsson E, Bjerke M, Malmgren H, Edman A, Wallin A, Nordlund A (2013) A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia. J Alzheimers Dis 36, 421-431.
8. Cui Y, Liu B, Luo S, Zhen X, Fan M, Liu T, Zhu W, Park M, Jiang T, Jin JS (2011) Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PloS One 6, e21896.
9. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK (2011) Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 77, 1619-1628.
10. Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Handels R, L'Italien G, van der Flier W, Aalten P, Teunissen C, Barkhof F, Blennow K, Wolz R, Rueckert D, Verhey F, Visser PJ (2012) Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging 33, 2272-2281.
11. Ewers M,Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, Feldman HH, Bokde AL, Alexander GE, Scheltens P, Vellas B, Dubois B, Weiner M, Hampel H (2012) Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 33, 1203-1214.
12. Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR Jr, Aisen PS, Thal LJ (2008) Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 70, 191-199.
13. van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F, Blankenstein MA, Scheltens P (2012) Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J Alzheimers Dis 29, 319-327.
14. Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A (2005) The Goteborg MCI study: Mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 76, 1485-1490.
15. Reisberg B, Ferris SH, de Leon MJ, Crook T (1988) Global Deterioration Scale (GDS). Psychopharmacol Bull 24, 661-663.
16. Wallin A, Edman A, Blennow K, Gottfries CG, Karlsson I, Regland B, Sjogren M (1996) Stepwise comparative status analysis (STEP): A tool for identification of regional brain syndromes in dementia. J Geriatr Psychiatry Neurol 9, 185-199.
17. Royall DR, Mahurin RK, GrayKF(1992) Bedside assessment of executive cognitive impairment: The executive interview. J Am Geriatr Soc 40, 1221-1226.
18. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
19. Morris JC (1997) Clinical dementia rating: A reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 9(Suppl 1), 173-176; discussion 177-178.
20. Eckerstrom M, Skoogh J, Rolstad S, Gothlin M, Steineck G, Johansson B, Wallin A (2013) Sahlgrenska Academy Selfreported Cognitive Impairment Questionnaire (SASCI-Q)-a research tool discriminating between subjectively cognitively impaired patients and healthy controls. Int Psychogeriatr 25, 420-430.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
22. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW (2000) Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 59, 23-30.
23. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47, 1113-1124.
24. (1994) Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 57, 416-418.
25. Eckerström C, Olsson E, Borga M, Ekholm S, Ribbelin S, Rolstad S, Starck G, Edman A, Wallin A, Malmgren H (2008) Small baseline volume of left hippocampus is associated with subsequent conversion of MCI into dementia: The Goteborg MCI study. J Neurol Sci 272, 48-59.
26. Eckerström C, Olsson E, Klasson N, Bjerke M, Gothlin M, Jonsson M, Rolstad S, Malmgren H, Wallin A, Edman A (2011) High white matter lesion load is associated with hippocampal atrophy in mild cognitive impairment. Dementia Geriatr Cogn Disord 31, 132-138.
27. Convit A, McHugh P, Wolf OT, de Leon MJ, Bobinski M, De Santi S, Roche A, Tsui W (1999) MRI volume of the amygdala: A reliable method allowing separation from the hippocampal formation. Psychiatry Res: Neuroimaging 90, 113-123.
28. Fischl B (2012) FreeSurfer. Neuroimage 62, 774-781.
29. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA (1987) MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 149, 351-356.
30. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999) Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56, 673-680.
31. Geffen GM, Butterworth P, Geffen LB (1994) Test-retest reliability of a new form of the auditory verbal learning test (AVLT). Arch Clin Neuropsychol 9, 303-316.
32. Reitan RM (1985) The Halstead-Reitan Neuropsychological Test Battery, Neuropsychological Press, Tucson, AZ.
33. Kaplan EG, Weintraub S (1983) The Boston Naming Test (2nd ed.), Lea&Febinger, Philadelphia.
34. (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357, 169-175.
35. Mendez MF (2012) Early-onset Alzheimer's disease: Nonamnestic subtypes and type 2 AD. Arch Med Res 43, 677-685.
36. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
37. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78, 47-54.
38. Westman E, Aguilar C, Muehlboeck JS, Simmons A (2013) Regional magnetic resonance imaging measures for multivariate analysis in Alzheimer's disease and mild cognitive impairment. Brain Topogr 26, 9-23.
39. Shiino A, Watanabe T, Maeda K, Kotani E, Akiguchi I, Matsuda M (2006) Four subgroups of Alzheimer's disease based on patterns of atrophy using VBM and a unique pattern for early onset disease. Neuroimage 33, 17-26.
40. Du AT, Schuff N, Laakso MP, Zhu XP, Jagust WJ, Yaffe K, Kramer JH, Miller BL, Reed BR, Norman D, Chui HC, Weiner MW(2002) Effects of subcortical ischemic vascular dementia and ADon entorhinal cortex and hippocampus. Neurology 58, 1635-1641.
41. Geuze E, Vermetten E, Bremner JD (2005) MR-based in vivo hippocampal volumetrics: 2. Findings in neuropsychiatric disorders. Mol Psychiatry 10, 160-184.
42. Kim H, Chupin M, Colliot O, Bernhardt BC, Bernasconi N, Bernasconi A (2012) Automatic hippocampal segmentation in temporal lobe epilepsy: Impact of developmental abnormalities. Neuroimage 59, 3178-3186.
43. Twamley EW, Ropacki SA, BondiMW(2006) Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease. J Int Neuropsychol Soc 12, 707-735.
44. Liu Y, Paajanen T, Zhang Y, Westman E, Wahlund LO, Simmons A, Tunnard C, Sobow T, Mecocci P, Tsolaki M, Vellas B, Muehlboeck S, Evans A, Spenger C, Lovestone S, Soininen H (2010) Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 31, 1375-1385.